Pravigard Pac (copackaged) is a drug owned by Bristol Myers Squibb Co. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 22, 2014. Details of Pravigard Pac (copackaged)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5622985 (Pediatric) | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
Oct, 2014
(10 years ago) |
Expired
|
| US5622985 | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
Apr, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Pravigard Pac (copackaged) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Pravigard Pac (copackaged)'s family patents as well as insights into ongoing legal events on those patents.
Pravigard Pac (copackaged)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Pravigard Pac (copackaged)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 22, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pravigard Pac (copackaged) Generics:
There are no approved generic versions for Pravigard Pac (copackaged) as of now.
Alternative Brands for Pravigard Pac (copackaged)
Pravigard Pac (copackaged) which is used for secondary prevention of coronary events in men and women with normal cholesterol levels who have had a myocardial infarction., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bristol Myers Squibb |
| |||
About Pravigard Pac (copackaged)
Pravigard Pac (Copackaged) is a drug owned by Bristol Myers Squibb Co. It is used for secondary prevention of coronary events in men and women with normal cholesterol levels who have had a myocardial infarction. Pravigard Pac (Copackaged) uses Aspirin; Pravastatin Sodium as an active ingredient. Pravigard Pac (Copackaged) was launched by Bristol Myers Squibb in 2003.
Approval Date:
Pravigard Pac (copackaged) was approved by FDA for market use on 24 June, 2003.
Active Ingredient:
Pravigard Pac (copackaged) uses Aspirin; Pravastatin Sodium as the active ingredient. Check out other Drugs and Companies using Aspirin; Pravastatin Sodium ingredient
Treatment:
Pravigard Pac (copackaged) is used for secondary prevention of coronary events in men and women with normal cholesterol levels who have had a myocardial infarction.
Dosage:
Pravigard Pac (copackaged) is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 81MG;80MG | TABLET | Discontinued | ORAL |
| 325MG;40MG | TABLET | Discontinued | ORAL |
| 325MG;80MG | TABLET | Discontinued | ORAL |
| 325MG;20MG | TABLET | Discontinued | ORAL |
| 81MG;20MG | TABLET | Discontinued | ORAL |
| 81MG;40MG | TABLET | Discontinued | ORAL |